The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug ...

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP. New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for ...

President Donald Trump signed an executive order Monday that he said will slash drug prices by approximately 59% or more ...

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra ... approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia Syndrome (FCS). The European Commission’s conditional ...

FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and ...

Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

MAPLE-HCM met its primary endpoint, demonstrating a statistically significant improvement in peak oxygen uptake (pVO 2) from ...

Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional ...

FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and Intern ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long ...

OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain ...